Status of chemotherapy for testis cancer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Significant advances have been made in the treatment of advanced testicular cancer. These advances have been centered on better staging techniques with procedures such as computed tomography as well as the development of reliable serum markers. Based on these techniques, patients can be directed toward primary surgical therapy or systemic therapy. Cisplatin combination chemotherapy can be expected to cure approximately 80 per cent of all patients with advanced disease. Currently, cisplatin plus etopside plus bleomycin is the standard treatment for patients with advanced disease. Newer trials are currently addressing the role of more aggressive therapy in patients with a poor prognosis while parallel trials examine the possibility of minimizing toxicity for those patients with good-risk disease.

Original languageEnglish
Pages (from-to)713-720
Number of pages8
JournalUrologic Clinics of North America
Volume14
Issue number4
StatePublished - 1987

Fingerprint

Testicular Neoplasms
Drug Therapy
Cisplatin
Therapeutics
Bleomycin
Combination Drug Therapy
Biomarkers
Tomography

ASJC Scopus subject areas

  • Urology

Cite this

Status of chemotherapy for testis cancer. / Loehrer, Patrick; Williams, S. D.; Einhorn, Lawrence.

In: Urologic Clinics of North America, Vol. 14, No. 4, 1987, p. 713-720.

Research output: Contribution to journalArticle

@article{cc0ecfb659e04daa846ef534961c81fe,
title = "Status of chemotherapy for testis cancer",
abstract = "Significant advances have been made in the treatment of advanced testicular cancer. These advances have been centered on better staging techniques with procedures such as computed tomography as well as the development of reliable serum markers. Based on these techniques, patients can be directed toward primary surgical therapy or systemic therapy. Cisplatin combination chemotherapy can be expected to cure approximately 80 per cent of all patients with advanced disease. Currently, cisplatin plus etopside plus bleomycin is the standard treatment for patients with advanced disease. Newer trials are currently addressing the role of more aggressive therapy in patients with a poor prognosis while parallel trials examine the possibility of minimizing toxicity for those patients with good-risk disease.",
author = "Patrick Loehrer and Williams, {S. D.} and Lawrence Einhorn",
year = "1987",
language = "English",
volume = "14",
pages = "713--720",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Status of chemotherapy for testis cancer

AU - Loehrer, Patrick

AU - Williams, S. D.

AU - Einhorn, Lawrence

PY - 1987

Y1 - 1987

N2 - Significant advances have been made in the treatment of advanced testicular cancer. These advances have been centered on better staging techniques with procedures such as computed tomography as well as the development of reliable serum markers. Based on these techniques, patients can be directed toward primary surgical therapy or systemic therapy. Cisplatin combination chemotherapy can be expected to cure approximately 80 per cent of all patients with advanced disease. Currently, cisplatin plus etopside plus bleomycin is the standard treatment for patients with advanced disease. Newer trials are currently addressing the role of more aggressive therapy in patients with a poor prognosis while parallel trials examine the possibility of minimizing toxicity for those patients with good-risk disease.

AB - Significant advances have been made in the treatment of advanced testicular cancer. These advances have been centered on better staging techniques with procedures such as computed tomography as well as the development of reliable serum markers. Based on these techniques, patients can be directed toward primary surgical therapy or systemic therapy. Cisplatin combination chemotherapy can be expected to cure approximately 80 per cent of all patients with advanced disease. Currently, cisplatin plus etopside plus bleomycin is the standard treatment for patients with advanced disease. Newer trials are currently addressing the role of more aggressive therapy in patients with a poor prognosis while parallel trials examine the possibility of minimizing toxicity for those patients with good-risk disease.

UR - http://www.scopus.com/inward/record.url?scp=0023628122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023628122&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 713

EP - 720

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 4

ER -